fenofibrate has been researched along with Disease Exacerbation in 46 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| "Experimental studies suggest that fenofibrate prevents abdominal aortic aneurysm (AAA) development by lowering aortic osteopontin (OPN) concentration and reducing the number of macrophages infiltrating the aortic wall." | 9.34 | A Randomised Controlled Trial Assessing the Effects of Peri-operative Fenofibrate Administration on Abdominal Aortic Aneurysm Pathology: Outcomes From the FAME Trial. ( Cavaye, D; Golledge, J; Jaeggi, R; Jenkins, JS; Lazzaroni, SM; Moran, CS; Morton, SK; Moxon, JV; Pinchbeck, JL; Quigley, F; Reid, CM; Rowbotham, SE, 2020) |
| "The purpose of this study is to study the benefit of addition of oral fenofibrate to the current regimen of diabetic macular edema (DME) management and quantify its effect on macular thickness and visual function in DME." | 9.27 | Efficiency of fenofibrate in facilitating the reduction of central macular thickness in diabetic macular edema. ( Hande, P; Murali, S; Shetty, J; Srinivasan, S, 2018) |
| "The combination of antihypertensive agents with micronized fenofibrate can effectively prevent the progression of carotid atherosclerosis and reduce the incidence of stroke in patients with essential hypertension." | 9.12 | Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. ( Meng, QH; Su, G; Zhu, S, 2006) |
| "Improvement in lipid profiles with fenofibrate in patients with type 2 diabetes was associated with reduced progression from normal albumin excretion to microalbuminuria." | 9.11 | Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). ( Ansquer, JC; Foucher, C; Rattier, S; Steiner, G; Taskinen, MR, 2005) |
| "The drug fenofibrate has received major attention as a novel medical treatment for diabetic retinopathy (DR) and other diabetes-induced microvascular complications." | 8.89 | An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. ( Jenkins, AJ; Keech, AC; Lamoureux, EL; Ma, JX; Noonan, JE; Wang, JJ, 2013) |
| "To review clinical and experimental data for fenofibrate as a possible systemic treatment for diabetic retinopathy." | 8.88 | Fenofibrate - a potential systemic treatment for diabetic retinopathy? ( Mitchell, P; Simó, R; Wong, TY, 2012) |
| "Numerous studies have reported the efficacy of fenofibrate for patients with diabetic retinopathy (DRP)." | 7.91 | Efficacy of fenofibrate for diabetic retinopathy: A systematic review protocol. ( Han, L; Liu, HW; Qi, YX; Su, XJ, 2019) |
| "Diabetic retinopathy is a significant cause of vision impairment, especially affecting those of working age." | 6.52 | The use of fenofibrate in the management of patients with diabetic retinopathy: an evidence-based review. ( Newman, D; Ong, J; Ooi, JL; Sharma, N, 2015) |
| "Fenofibrate also has a favorable impact on a number of nonlipid residual risk factors associated with type 2 diabetes and metabolic syndrome, mediated by peroxisome proliferator-activated receptor-alpha." | 6.44 | Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus. ( Steiner, G, 2008) |
| "Experimental studies suggest that fenofibrate prevents abdominal aortic aneurysm (AAA) development by lowering aortic osteopontin (OPN) concentration and reducing the number of macrophages infiltrating the aortic wall." | 5.34 | A Randomised Controlled Trial Assessing the Effects of Peri-operative Fenofibrate Administration on Abdominal Aortic Aneurysm Pathology: Outcomes From the FAME Trial. ( Cavaye, D; Golledge, J; Jaeggi, R; Jenkins, JS; Lazzaroni, SM; Moran, CS; Morton, SK; Moxon, JV; Pinchbeck, JL; Quigley, F; Reid, CM; Rowbotham, SE, 2020) |
| "The purpose of this study is to study the benefit of addition of oral fenofibrate to the current regimen of diabetic macular edema (DME) management and quantify its effect on macular thickness and visual function in DME." | 5.27 | Efficiency of fenofibrate in facilitating the reduction of central macular thickness in diabetic macular edema. ( Hande, P; Murali, S; Shetty, J; Srinivasan, S, 2018) |
| "9%, respectively) and also for dyslipidemia (160 mg daily of fenofibrate plus simvastatin or placebo plus simvastatin) or for systolic blood-pressure control (target, <120 or <140 mm Hg)." | 5.14 | Effects of medical therapies on retinopathy progression in type 2 diabetes. ( Ambrosius, WT; Chew, EY; Cushman, WC; Danis, RP; Davis, MD; Elam, MB; Esser, BA; Fine, LJ; Gangaputra, S; Genuth, S; Gerstein, HC; Ginsberg, HN; Goff, DC; Greven, CM; Hubbard, L; Lovato, JF; Perdue, LH; Schubart, U, 2010) |
| "The combination of antihypertensive agents with micronized fenofibrate can effectively prevent the progression of carotid atherosclerosis and reduce the incidence of stroke in patients with essential hypertension." | 5.12 | Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. ( Meng, QH; Su, G; Zhu, S, 2006) |
| "Improvement in lipid profiles with fenofibrate in patients with type 2 diabetes was associated with reduced progression from normal albumin excretion to microalbuminuria." | 5.11 | Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). ( Ansquer, JC; Foucher, C; Rattier, S; Steiner, G; Taskinen, MR, 2005) |
| " Fenofibrate significantly slowed the progression of early diabetic retinopathy by 30 to 40% within 4 to 5 years in patients with type 2 diabetes mellitus and pre-existing retinopathy at baseline." | 4.93 | Effect of micronized fenofibrate on microvascular complications of type 2 diabetes: a systematic review. ( Czupryniak, L; Gogtay, JA; Joshi, SR; Lopez, M, 2016) |
| "The drug fenofibrate has received major attention as a novel medical treatment for diabetic retinopathy (DR) and other diabetes-induced microvascular complications." | 4.89 | An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. ( Jenkins, AJ; Keech, AC; Lamoureux, EL; Ma, JX; Noonan, JE; Wang, JJ, 2013) |
| "To review clinical and experimental data for fenofibrate as a possible systemic treatment for diabetic retinopathy." | 4.88 | Fenofibrate - a potential systemic treatment for diabetic retinopathy? ( Mitchell, P; Simó, R; Wong, TY, 2012) |
| "Numerous studies have reported the efficacy of fenofibrate for patients with diabetic retinopathy (DRP)." | 3.91 | Efficacy of fenofibrate for diabetic retinopathy: A systematic review protocol. ( Han, L; Liu, HW; Qi, YX; Su, XJ, 2019) |
| "Treatment with fenofibrate did reduce all cardiovascular disease (CVD) events, the secondary end point (by 11%, p = 0." | 2.73 | After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate. ( Sacks, FM, 2008) |
| "Eighteen patients with hyperlipidemia and type 2 diabetes mellitus." | 2.72 | Effects of fenofibrate therapy on plasma ubiquinol-10 and ubiquinone-10 levels in Japanese patients with hyperlipidemia and type 2 diabetes mellitus. ( Asano, A; Inazu, A; Kawashiri, MA; Kobayashi, J; Mabuchi, H; Murase, Y; Nohara, A; Shimizu, M, 2006) |
| "A total of 418 subjects with type 2 diabetes were randomly assigned to 200 mg micronized fenofibrate daily or placebo." | 2.71 | Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). ( Ansquer, JC; Aubin, F; Foucher, C; Hamsten, A; Rattier, S; Steiner, G; Taskinen, MR; Vakkilainen, J, 2003) |
| "Disease progression is associated with variation in AAT, and low AAT levels promote atherogenesis." | 2.71 | Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene. ( Flavell, DM; Frick, MH; Humphries, SE; Jackson, R; Kesäniemi, YA; Martin, S; Nagl, S; Nieminen, MS; Pasternack, A; Steiner, G; Syvänne, M; Talmud, PJ; Taskinen, MR; Whitehouse, DB, 2003) |
| "Diabetic retinopathy is a significant cause of vision impairment, especially affecting those of working age." | 2.52 | The use of fenofibrate in the management of patients with diabetic retinopathy: an evidence-based review. ( Newman, D; Ong, J; Ooi, JL; Sharma, N, 2015) |
| "Especially diabetic nephropathy is a leading cause of morbidity and mortality, and its prevalence is increasing." | 2.48 | Fibrates: therapeutic potential for diabetic nephropathy? ( Kouroumichakis, I; Liakopoulos, V; Maltezos, E; Mikhailidis, DP; Papanas, N; Zarogoulidis, P, 2012) |
| "Microalbuminuria is an early marker of diabetic nephropathy and an independent risk factor for cardiovascular disease." | 2.44 | Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection. ( Brown, WV, 2008) |
| "Fenofibrate also has a favorable impact on a number of nonlipid residual risk factors associated with type 2 diabetes and metabolic syndrome, mediated by peroxisome proliferator-activated receptor-alpha." | 2.44 | Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus. ( Steiner, G, 2008) |
| "Multifactorial diseases such as type 2 diabetes mellitus (T2DM), are driven by a complex network of interconnected mechanisms that translate to a diverse range of complications at the physiological level." | 1.40 | Network signatures link hepatic effects of anti-diabetic interventions with systemic disease parameters. ( Kelder, T; Radonjic, M; van Gool, AJ; van Ommen, B; Verschuren, L, 2014) |
| "The development of diabetic nephropathy was assessed biochemically and histologically." | 1.36 | The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy. ( Arora, MK; Balakumar, P; Reddy, K, 2010) |
| "Fenofibrate treatment decreased hepatic macrophage accumulation and abolished steatosis." | 1.33 | Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. ( Buffat, L; Gijbels, MJ; Hofker, MH; Maeda, N; Noel, B; Shiri-Sverdlov, R; Staels, B; van Bilsen, M; van Gorp, PJ; Wouters, K, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.17) | 18.2507 |
| 2000's | 14 (30.43) | 29.6817 |
| 2010's | 26 (56.52) | 24.3611 |
| 2020's | 5 (10.87) | 2.80 |
| Authors | Studies |
|---|---|
| Okabayashi, Y | 1 |
| Nagasaka, S | 1 |
| Kanzaki, G | 1 |
| Tsuboi, N | 1 |
| Yokoo, T | 1 |
| Shimizu, A | 1 |
| Lefere, S | 1 |
| Puengel, T | 1 |
| Hundertmark, J | 1 |
| Penners, C | 1 |
| Frank, AK | 1 |
| Guillot, A | 1 |
| de Muynck, K | 1 |
| Heymann, F | 1 |
| Adarbes, V | 1 |
| Defrêne, E | 1 |
| Estivalet, C | 1 |
| Geerts, A | 1 |
| Devisscher, L | 1 |
| Wettstein, G | 1 |
| Tacke, F | 1 |
| Moxon, JV | 2 |
| Rowbotham, SE | 1 |
| Pinchbeck, JL | 1 |
| Lazzaroni, SM | 1 |
| Morton, SK | 1 |
| Moran, CS | 1 |
| Quigley, F | 1 |
| Jenkins, JS | 1 |
| Reid, CM | 1 |
| Cavaye, D | 1 |
| Jaeggi, R | 1 |
| Golledge, J | 2 |
| Yen, CL | 1 |
| Fan, PC | 1 |
| Lin, MS | 1 |
| Lee, CC | 1 |
| Tu, KH | 1 |
| Chen, CY | 1 |
| Hsiao, CC | 1 |
| Hsu, HH | 1 |
| Tian, YC | 1 |
| Chang, CH | 1 |
| Chekaoui, A | 1 |
| Ertl, HCJ | 1 |
| Srinivasan, S | 1 |
| Hande, P | 1 |
| Shetty, J | 1 |
| Murali, S | 1 |
| Maas, R | 1 |
| Mieth, M | 1 |
| Titze, SI | 1 |
| Hübner, S | 1 |
| Fromm, MF | 1 |
| Kielstein, JT | 1 |
| Schmid, M | 1 |
| Köttgen, A | 1 |
| Kronenberg, F | 1 |
| Krane, V | 1 |
| Hausknecht, B | 1 |
| Eckardt, KU | 1 |
| Schneider, MP | 1 |
| Su, XJ | 1 |
| Han, L | 1 |
| Qi, YX | 1 |
| Liu, HW | 1 |
| Simó, R | 2 |
| Roy, S | 1 |
| Behar-Cohen, F | 1 |
| Keech, A | 1 |
| Mitchell, P | 4 |
| Wong, TY | 3 |
| Hu, Z | 1 |
| Huang, S | 1 |
| Wu, Y | 1 |
| Liu, Y | 1 |
| Liu, X | 1 |
| Su, D | 1 |
| Tao, Y | 1 |
| Fu, P | 1 |
| Zhang, X | 1 |
| Peng, Z | 1 |
| Zhang, S | 1 |
| Yang, Y | 1 |
| Noonan, JE | 1 |
| Jenkins, AJ | 2 |
| Ma, JX | 1 |
| Keech, AC | 2 |
| Wang, JJ | 2 |
| Lamoureux, EL | 1 |
| Waldman, B | 1 |
| Davis, TM | 1 |
| Taskinen, MR | 4 |
| Scott, R | 1 |
| O'Connell, RL | 1 |
| Gebski, VJ | 1 |
| Ng, MK | 1 |
| Chew, EY | 2 |
| Davis, MD | 2 |
| Danis, RP | 2 |
| Lovato, JF | 2 |
| Perdue, LH | 2 |
| Greven, C | 1 |
| Genuth, S | 2 |
| Goff, DC | 2 |
| Leiter, LA | 1 |
| Ismail-Beigi, F | 1 |
| Ambrosius, WT | 2 |
| Kelder, T | 1 |
| Verschuren, L | 1 |
| van Ommen, B | 1 |
| van Gool, AJ | 1 |
| Radonjic, M | 1 |
| Sharma, N | 1 |
| Ooi, JL | 1 |
| Ong, J | 1 |
| Newman, D | 1 |
| Esmaeili, MA | 1 |
| Yadav, S | 1 |
| Gupta, RK | 1 |
| Waggoner, GR | 1 |
| Deloach, A | 1 |
| Calingasan, NY | 1 |
| Beal, MF | 1 |
| Kiaei, M | 1 |
| Czupryniak, L | 1 |
| Joshi, SR | 1 |
| Gogtay, JA | 1 |
| Lopez, M | 1 |
| Robinson, JG | 1 |
| Brown, WV | 1 |
| Steiner, G | 5 |
| Sacks, FM | 1 |
| Tsimihodimos, V | 1 |
| Liberopoulos, E | 1 |
| Elisaf, M | 1 |
| Arora, MK | 1 |
| Reddy, K | 1 |
| Balakumar, P | 1 |
| Foucher, C | 3 |
| Brugère, L | 1 |
| Ansquer, JC | 3 |
| Klein, BE | 1 |
| Gangaputra, S | 1 |
| Greven, CM | 1 |
| Hubbard, L | 1 |
| Esser, BA | 1 |
| Cushman, WC | 1 |
| Ginsberg, HN | 1 |
| Elam, MB | 1 |
| Gerstein, HC | 1 |
| Schubart, U | 1 |
| Fine, LJ | 1 |
| Lim, LS | 1 |
| Liew, G | 2 |
| Cheung, N | 1 |
| Giral, P | 1 |
| Rosenbaum, D | 1 |
| Baum, SJ | 1 |
| Egan, A | 1 |
| Byrne, M | 1 |
| Moustafa, T | 1 |
| Fickert, P | 1 |
| Magnes, C | 1 |
| Guelly, C | 1 |
| Thueringer, A | 1 |
| Frank, S | 1 |
| Kratky, D | 1 |
| Sattler, W | 1 |
| Reicher, H | 1 |
| Sinner, F | 1 |
| Gumhold, J | 1 |
| Silbert, D | 1 |
| Fauler, G | 1 |
| Höfler, G | 1 |
| Lass, A | 1 |
| Zechner, R | 1 |
| Trauner, M | 1 |
| Kouroumichakis, I | 1 |
| Papanas, N | 1 |
| Zarogoulidis, P | 1 |
| Liakopoulos, V | 1 |
| Maltezos, E | 1 |
| Mikhailidis, DP | 1 |
| Davidson, M | 1 |
| Rosenson, RS | 1 |
| Maki, KC | 1 |
| Nicholls, SJ | 1 |
| Ballantyne, CM | 1 |
| Setze, C | 1 |
| Carlson, DM | 1 |
| Stolzenbach, J | 1 |
| Krishna, SM | 1 |
| Seto, SW | 1 |
| Rush, C | 1 |
| Walker, PJ | 1 |
| Norman, PE | 1 |
| Vakkilainen, J | 1 |
| Aubin, F | 1 |
| Rattier, S | 2 |
| Hamsten, A | 1 |
| Talmud, PJ | 1 |
| Martin, S | 1 |
| Flavell, DM | 1 |
| Whitehouse, DB | 1 |
| Nagl, S | 1 |
| Jackson, R | 1 |
| Frick, MH | 1 |
| Nieminen, MS | 1 |
| Kesäniemi, YA | 2 |
| Pasternack, A | 1 |
| Humphries, SE | 1 |
| Syvänne, M | 1 |
| Jokinen, V | 1 |
| Ukkola, O | 1 |
| Airaksinen, KE | 1 |
| Koistinen, JM | 1 |
| Ikäheimo, MJ | 1 |
| Huikuri, HV | 1 |
| Shiri-Sverdlov, R | 1 |
| Wouters, K | 1 |
| van Gorp, PJ | 1 |
| Gijbels, MJ | 1 |
| Noel, B | 1 |
| Buffat, L | 1 |
| Staels, B | 1 |
| Maeda, N | 1 |
| van Bilsen, M | 1 |
| Hofker, MH | 1 |
| Asano, A | 1 |
| Kobayashi, J | 1 |
| Murase, Y | 1 |
| Nohara, A | 1 |
| Kawashiri, MA | 1 |
| Inazu, A | 1 |
| Shimizu, M | 1 |
| Mabuchi, H | 1 |
| Zhu, S | 1 |
| Su, G | 1 |
| Meng, QH | 1 |
| McLaughlin, PR | 1 |
| Gladstone, P | 1 |
| Forster, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Oral Fenofibrate on Retinal Thickness and Macular Volume: Assessments on Retinal Endothelial Vascular Dysfunction, Inflammation, and Angiogenesis in Diabetic Retinopathy With Dyslipidemia[NCT04885153] | 36 participants (Actual) | Interventional | 2016-11-01 | Completed | |||
| Action to Control Cardiovascular Risk in Diabetes (ACCORD)[NCT00000620] | Phase 3 | 10,251 participants (Actual) | Interventional | 1999-09-30 | Completed | ||
| Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study[NCT00542178] | Phase 3 | 3,472 participants (Actual) | Interventional | 2003-10-31 | Completed | ||
| Clinical Study to Evaluate the Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients[NCT06155331] | Phase 4 | 44 participants (Anticipated) | Interventional | 2023-12-31 | Recruiting | ||
| Evaluation of Choline Fenofibrate (ABT-335) on Carotid Intima-Media Thickness (cIMT) in Subjects With Type IIb Dyslipidemia With Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial[NCT00616772] | Phase 3 | 682 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Effects of Fenofibrate Administration in Patients With Diabetic Nephropathy[NCT03869931] | Phase 3 | 300 participants (Anticipated) | Interventional | 2019-03-08 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Time to death from any cause. Secondary measure for Glycemia Trial.~A finding of higher mortality in the intensive-therapy group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid)." (NCT00000620)
Timeframe: 4.9 years
| Intervention | participants (Number) |
|---|---|
| Glycemia Trial: Intensive Control | 391 |
| Glycemia Trial: Standard Control | 327 |
"Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. This was the primary outcome measure in all three trials: Glycemia (all participants), Blood Pressure (subgroup of participants not in Lipid Trial), and Lipid (subgroup of participants not in Blood Pressure Trial).~In the Glycemia Trial, a finding of higher mortality in the intensive arm group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid) to their planned completion." (NCT00000620)
Timeframe: 4.9 years
| Intervention | participants (Number) |
|---|---|
| Glycemia Trial: Intensive Control | 503 |
| Glycemia Trial: Standard Control | 543 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Primary outcome for Blood Pressure Trial. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| BP Trial: Intensive Control | 208 |
| BP Trial: Standard Control | 237 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| Lipid Trial: Fenofibrate | 291 |
| Lipid Trial: Placebo | 310 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, revascularization procedure or hospitalization for CHF in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| Lipid Trial: Fenofibrate | 641 |
| Lipid Trial: Placebo | 667 |
Time to first occurrence of nonfatal or fatal stroke among participants in the BP Trial. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| BP Trial: Intensive Control | 36 |
| BP Trial: Standard Control | 62 |
(NCT00542178)
Timeframe: Measured at Year 4
| Intervention | Participants (Count of Participants) |
|---|---|
| Intensive Glycemia Control | 547 |
| Standard Glycemia Control | 623 |
| Intensive Blood Pressure Control | 266 |
| Standard Blood Pressure Control | 300 |
| Fenofibrate + Simvastatin Therapy | 305 |
| Placebo + Simvastatin Therapy | 299 |
(NCT00542178)
Timeframe: Measured at Year 4
| Intervention | Participants (Count of Participants) |
|---|---|
| Intensive Glycemia Control | 44 |
| Standard Glycemia Control | 40 |
| Intensive Blood Pressure Control | 18 |
| Standard Blood Pressure Control | 20 |
| Fenofibrate + Simvastatin Therapy | 24 |
| Placebo + Simvastatin Therapy | 22 |
(NCT00542178)
Timeframe: Measured at Year 4
| Intervention | Participants (Count of Participants) |
|---|---|
| Intensive Glycemia Control | 744 |
| Standard Glycemia Control | 752 |
| Intensive Blood Pressure Control | 367 |
| Standard Blood Pressure Control | 382 |
| Fenofibrate + Simvastatin Therapy | 354 |
| Placebo + Simvastatin Therapy | 393 |
Diabetic retinopathy status was defined according to the eye with the highest level on the ETDRS Final Severity Scale for Persons, as follows: no diabetic retinopathy, a level of less than 20; mild diabetic retinopathy, a level of 20; moderate nonproliferative diabetic retinopathy (NPDR), a level above 20 but less than 53; severe diabetic retinopathy, a level of 53 but less than 60; and proliferative diabetic retinopathy (PDR), a level of 60 or higher. (NCT00542178)
Timeframe: Measured at Year 4
| Intervention | participants (Number) |
|---|---|
| Intensive Glycemia Control | 104 |
| Standard Glycemia Control | 149 |
| Intensive Blood Pressure Control | 67 |
| Standard Blood Pressure Control | 54 |
| Fenofibrate + Simvastatin Therapy | 52 |
| Placebo + Simvastatin Therapy | 80 |
Rate of change (mm/year) from baseline in composite of mean of maximal posterior-wall and anterior-wall intima-media thickness (IMT) of the left and right common carotid artery, internal carotid artery, and carotid bifurcation. The statistical model used change from baseline as the dependent variable, with time of IMT assessment (in years) as one of the factors in the model. The between-group difference in the rate of change was based on the parameter coefficient for the time-by-treatment interaction. The within-group rate of change was obtained from estimate statements within the repeated measures analysis. IMT was measured using non-invasive ultrasound. (NCT00616772)
Timeframe: Baseline, 6 months, 12 months, 18 months, and 24 months
| Intervention | mm/year (Mean) |
|---|---|
| ABT-335 + Atorvastatin | -0.003 |
| Placebo + Atorvastatin | -0.019 |
Rate of change (mm/year) from baseline in composite of mean of maximal posterior-wall intima-media thickness (IMT) of the left and right common carotid artery, internal carotid artery, and carotid bifurcation. The statistical model used change from baseline as the dependent variable, with time of IMT assessment (in years) as one of the factors in the model. The between-group difference in the rate of change was based on the parameter coefficient for the time-by-treatment interaction. The within-group rate of change was obtained from estimate statements within the repeated measures analysis. IMT was measured using non-invasive ultrasound. (NCT00616772)
Timeframe: Baseline, 6 months, 12 months, 18 months, and 24 months
| Intervention | mm/year (Mean) |
|---|---|
| ABT-335 + Atorvastatin | -0.014 |
| Placebo + Atorvastatin | -0.008 |
Rate of change (mm/year) from baseline in composite of mean of the mean posterior-wall intima-media thickness (IMT) of the left and right common carotid artery, internal carotid artery, and carotid bifurcation. The statistical model used change from baseline as the dependent variable, with time of IMT assessment (in years) as one of the factors in the model. The between-group difference in the rate of change was based on the parameter coefficient for the time-by-treatment interaction. The within-group rate of change was obtained from estimate statements within the repeated measures analysis. IMT was measured using non-invasive ultrasound. (NCT00616772)
Timeframe: Baseline, 6 months, 12 months, 18 months, and 24 months
| Intervention | mm/year (Mean) |
|---|---|
| ABT-335 + Atorvastatin | -0.010 |
| Placebo + Atorvastatin | -0.004 |
Rate of change (mm/year) from baseline in mean of maximal posterior-wall carotid intima-media thickness (cIMT) of the left and right common carotid artery. The statistical model used change from baseline as the dependent variable, with time of cIMT assessment (in years) as one of the factors in the model. The between-group difference in the rate of change was based on the parameter coefficient for the time-by-treatment interaction. The within-group rate of change was obtained from estimate statements within the repeated measures analysis. cIMT was measured using non-invasive ultrasound. (NCT00616772)
Timeframe: Baseline, 6 months, 12 months, 18 months, and 24 months
| Intervention | mm/year (Mean) |
|---|---|
| ABT-335 + Atorvastatin | -0.005 |
| Placebo + Atorvastatin | -0.003 |
Rate of change (mm/year) from baseline in mean of posterior-wall carotid intima-media thickness (cIMT) of the left and right common carotid artery. The statistical model used change from baseline as the dependent variable, with time of cIMT assessment (in years) as one of the factors in the model. The between-group difference in the rate of change was based on the parameter coefficient for the time-by-treatment interaction. The within-group rate of change was obtained from estimate statements within the repeated measures analysis. cIMT was measured using non-invasive ultrasound. (NCT00616772)
Timeframe: Baseline, 6 months, 12 months, 18 months, and 24 months
| Intervention | mm/year (Mean) |
|---|---|
| ABT-335 + Atorvastatin | -0.006 |
| Placebo + Atorvastatin | 0.000 |
12 reviews available for fenofibrate and Disease Exacerbation
| Article | Year |
|---|---|
Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Fenofibrate; Humans; | 2013 |
An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes.
Topics: Diabetic Retinopathy; Disease Progression; Fenofibrate; Humans; Hypolipidemic Agents; Microvessels; | 2013 |
The use of fenofibrate in the management of patients with diabetic retinopathy: an evidence-based review.
Topics: Australia; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Fenofibrate; Humans | 2015 |
Effect of micronized fenofibrate on microvascular complications of type 2 diabetes: a systematic review.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Retinopathy; Disease Progression; Drug C | 2016 |
LDL reduction: how low should we go and is it safe?
Topics: Allylamine; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Colesevelam Hydrochloride; Coron | 2008 |
Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Dys | 2008 |
Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus.
Topics: Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Fenofibrat | 2008 |
Pleiotropic effects of fenofibrate.
Topics: Animals; Atherosclerosis; Disease Progression; Fenofibrate; Gene Expression Regulation; Humans; Hypo | 2009 |
How can we improve the management of vascular risk in type 2 diabetes: insights from FIELD.
Topics: Albuminuria; Amputation, Surgical; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 2009 |
Fenofibrate, homocysteine and renal function.
Topics: Animals; Biomarkers; Creatinine; Disease Progression; Dyslipidemias; Fenofibrate; Glomerular Filtrat | 2010 |
Fibrates: therapeutic potential for diabetic nephropathy?
Topics: Animals; Creatinine; Diabetic Nephropathies; Disease Progression; Fenofibrate; Fibric Acids; Humans; | 2012 |
Fenofibrate - a potential systemic treatment for diabetic retinopathy?
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Fenofibrate; Humans; Hypolipid | 2012 |
14 trials available for fenofibrate and Disease Exacerbation
| Article | Year |
|---|---|
A Randomised Controlled Trial Assessing the Effects of Peri-operative Fenofibrate Administration on Abdominal Aortic Aneurysm Pathology: Outcomes From the FAME Trial.
Topics: Aged; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Biomarkers; Disease Progression; Double-Blind Me | 2020 |
Efficiency of fenofibrate in facilitating the reduction of central macular thickness in diabetic macular edema.
Topics: Aged; Diabetic Retinopathy; Disease Progression; Dose-Response Relationship, Drug; Female; Fenofibra | 2018 |
HDL-C and HDL-C/ApoA-I predict long-term progression of glycemia in established type 2 diabetes.
Topics: Aged; Apolipoprotein A-I; Blood Glucose; Cholesterol, HDL; Cross-Sectional Studies; Diabetes Mellitu | 2014 |
The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study.
Topics: Aged; Cardiovascular Diseases; Cataract Extraction; Diabetes Mellitus, Type 2; Diabetic Retinopathy; | 2014 |
The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study.
Topics: Aged; Cardiovascular Diseases; Cataract Extraction; Diabetes Mellitus, Type 2; Diabetic Retinopathy; | 2014 |
The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study.
Topics: Aged; Cardiovascular Diseases; Cataract Extraction; Diabetes Mellitus, Type 2; Diabetic Retinopathy; | 2014 |
The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study.
Topics: Aged; Cardiovascular Diseases; Cataract Extraction; Diabetes Mellitus, Type 2; Diabetic Retinopathy; | 2014 |
After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; D | 2008 |
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabe | 2010 |
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabe | 2010 |
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabe | 2010 |
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabe | 2010 |
Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Carotid Arteries; Carotid Intima-Me | 2012 |
Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS).
Topics: Adult; Aged; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angi | 2003 |
Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene.
Topics: 3' Untranslated Regions; Aged; Alleles; alpha 1-Antitrypsin; alpha 1-Antitrypsin Deficiency; Amino A | 2003 |
Temporal changes in cardiovascular autonomic regulation in type II diabetic patients: association with coronary risk variables and progression of coronary artery disease.
Topics: Adult; Aged; Arteriosclerosis; Autonomic Nervous System; Coronary Angiography; Diabetes Mellitus, Ty | 2003 |
Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti | 2005 |
Effects of fenofibrate therapy on plasma ubiquinol-10 and ubiquinone-10 levels in Japanese patients with hyperlipidemia and type 2 diabetes mellitus.
Topics: Coenzymes; Diabetes Mellitus, Type 2; Disease Progression; Female; Fenofibrate; Humans; Hyperlipidem | 2006 |
Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension.
Topics: Anti-Inflammatory Agents; Antihypertensive Agents; Biomarkers; Carotid Artery Diseases; Demography; | 2006 |
Diabetes Atherosclerosis Intervention Study (DAIS): quantitative coronary angiographic analysis of coronary artery atherosclerosis.
Topics: Adult; Aged; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angi | 1998 |
20 other studies available for fenofibrate and Disease Exacerbation
| Article | Year |
|---|---|
Group 1 innate lymphoid cells are involved in the progression of experimental anti-glomerular basement membrane glomerulonephritis and are regulated by peroxisome proliferator-activated receptor α.
Topics: Animals; Anti-Glomerular Basement Membrane Disease; Biopsy; CD8 Antigens; Cells, Cultured; Chemokine | 2019 |
Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages
Topics: Animals; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Fatty Liver; | 2020 |
Fenofibrate Delays the Need for Dialysis and Reduces Cardiovascular Risk Among Patients With Advanced CKD.
Topics: Adult; Aged; Cardiovascular Diseases; Cohort Studies; Disease Progression; Female; Fenofibrate; Hear | 2021 |
PPARα Agonist Fenofibrate Enhances Cancer Vaccine Efficacy.
Topics: Animals; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Line; Disease Progression; Epitopes; Fema | 2021 |
Drugs linked to plasma homoarginine in chronic kidney disease patients-a cross-sectional analysis of the German Chronic Kidney Disease cohort.
Topics: Adolescent; Adult; Aged; Cohort Studies; Cross-Sectional Studies; Disease Progression; Female; Fenof | 2020 |
Efficacy of fenofibrate for diabetic retinopathy: A systematic review protocol.
Topics: Diabetic Retinopathy; Disease Progression; Fenofibrate; Humans; Hypolipidemic Agents; Macular Edema; | 2019 |
Hereditary features, treatment, and prognosis of the lipoprotein glomerulopathy in patients with the APOE Kyoto mutation.
Topics: Adolescent; Adult; Aged; Apolipoprotein E2; Biomarkers; Biopsy; Case-Control Studies; China; Creatin | 2014 |
Network signatures link hepatic effects of anti-diabetic interventions with systemic disease parameters.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Progression; Fenofibrate; Hydrocarbons, Fluorinated; Liv | 2014 |
Preferential PPAR-α activation reduces neuroinflammation, and blocks neurodegeneration in vivo.
Topics: Amyotrophic Lateral Sclerosis; Animals; Cell Death; Disease Models, Animal; Disease Progression; Fem | 2016 |
The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy.
Topics: Animals; Blood Glucose; Blood Urea Nitrogen; Creatinine; Diabetic Nephropathies; Disease Models, Ani | 2010 |
Reduction in risk of progression of diabetic retinopathy.
Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Drug | 2010 |
Mixed messages on systemic therapies for diabetic retinopathy.
Topics: Blood Glucose; Blood Pressure; Diabetic Retinopathy; Disease Progression; Fenofibrate; Humans; Hypol | 2010 |
Retinopathy progression in type 2 diabetes.
Topics: 2,3-Diphosphoglycerate; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Fenofi | 2010 |
Retinopathy progression in type 2 diabetes.
Topics: Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Drug Therapy | 2010 |
Retinopathy progression in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Fenofibrate; Humans; Hypertens | 2010 |
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Fenofibrate; Humans; Hypolipid | 2011 |
Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; | 2012 |
Fenofibrate increases high-density lipoprotein and sphingosine 1 phosphate concentrations limiting abdominal aortic aneurysm progression in a mouse model.
Topics: Angiotensin II; Animals; Aorta; Aorta, Thoracic; Aortic Aneurysm, Abdominal; Apoptosis; Azo Compound | 2012 |
Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates.
Topics: Animals; Apolipoprotein E2; Apolipoproteins E; ATP-Binding Cassette Transporters; Clofibric Acid; Di | 2006 |
[Milestone in the treatment of diabetic dyslipidemia: the DAIS Study].
Topics: Adult; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Disease Progression | 2001 |